nach oben

Erschienen in:

06.03.2023 | Original article

Patient-reported outcome measurements in a selective cohort of relapsing–remitting multiple sclerosis patients: relationships with physical disability, cognitive impairment, and MRI-derived metrics

verfasst von: Frédéric London, Souraya El Sankari, Alice De Haan, Zohra Benyahia, Gaëtane Landenne, Thierry Duprez, Vincent van Pesch

Erschienen in: Acta Neurologica Belgica | Ausgabe 3/2023

Einloggen, um Zugang zu erhalten

Abstract

Background

The added value of patient-reported outcome measures (PROMs) in addition to standard clinical outcome tools in the assessment of relapsing–remitting multiple sclerosis (RRMS) patients’ status is increasingly recognized. PROMs facilitate the detection of hidden aspects of MS and help to integrate the patient’s subjective experience of health-related quality of life (HRQoL) status and treatment satisfaction in a holistic way. However, the relationship between PROMs and clinical and cognitive status has been scarcely investigated up to now.

Objective

To investigate the association of PROMs with physical and cognitive disability in a cohort of RRMS patients at initiation of a new disease-modifying treatment.

Methods

In this cross-sectional bicenter study, 59 consecutive RRMS patients underwent neurological examination with EDSS assessment, comprehensive cognitive tests (BVMT-R, SDMT, CVLT-II) and a set of self-reported questionnaires. Lesion and brain volumes were analyzed and processed by the automated MSmetrix^® software (Icometrix^®, Leuven, Belgium). Spearman’s correlation coefficient was used to evaluate the association of collected variables. A cross-sectional logistic regression analysis was performed to find baseline correlates of cognitive impairment.

Results

Of the 59 RRMS patients (mean age 39 ± 9.8 years, 79.7% female, median EDSS 2.0), 33 (56%) had cognitive impairment. While almost all dimensions of health, explored by PROMs, were impacted in the overall sample, no significant difference was observed in patients with and without cognitive impairment. All PROMs were significantly associated with EDSS (R = 0.37–0.55; p < 0.05), except for the psychological component of MSIS-29, BDI and DEX-Q scores. No significant correlation was found between PROMs and cognitive performances. The cross-sectional logistic regression analysis included age, gender (female), education, EDSS, hippocampus and FLAIR lesion volumes as significant predictors of cognitive impairment.

Conclusions

The data highlight that PROMs provide valuable information on the well-being of PwMS closely paralleling the extent of MS-related disability, as measured by the EDSS. Additional research should determine the relevance of PROMs as longitudinal outcome measures.

Nur mit Berechtigung zugänglich

Lublin FD, Reingold SC, Cohen JA, Cutter GR, Sørensen PS, Thompson AJ et al (2014) Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology 83(3):278–286. https://doi.org/10.1212/WNL.0000000000000560CrossRefPubMedPubMedCentral

Kobelt G, Thompson A, Berg J, Gannedahl M, Eriksson J, MSCOI Study Group (2017) European multiple sclerosis platform new insights into the burden and costs of multiple sclerosis in Europe. Mult Scler 23(8):1123–1136. https://doi.org/10.1177/1352458517694432CrossRefPubMedPubMedCentral

van’t Hullenaar CAA, Coerver E, Kalkers NF, van Kempen Z, Koch M, Uitdehaag BMJ, Killestein J, Strijbis EMM (2021) The use of multi-domain patient reported outcome measures for detecting clinical disease progression in multiple sclerosis. Mult Scler Relat Disord 55:103165. https://doi.org/10.1016/j.msard.2021.103165CrossRef

Macaron G, Baldassari LE, Nakamura K, Rao SM, McGingley MP, Boss BP, Li H, Miller DM, Jones SE, Bermel RA, Cohen JA, D’Ontaneda D, Conway DS (2020) Cognitive processing speed in multiple sclerosis clinical practice: association with patient-reported outcomes, employment and magnetic resonance metrics. Eur J Neurol 27:1238–1249. https://doi.org/10.1111/ene.14239CrossRefPubMed

Langdon DW, Amato MP, Boringa J, Brochet B, Foley F, Fredrikson S, Hämäläinen P, Hartung H-P, Krupp L, Penner IK, Reder AT, Benedict RHB (2012) Recommendations for a brief international cognitive assessment for multiple sclerosis (BICAMS). Mult Scler 18:891–898. https://doi.org/10.1177/1352458511431076CrossRefPubMedPubMedCentral

Benedict RHB (1997) Brief visuospatial memory test-revised: professional manual. Psychological Assessment Resources Inc., Odessa

Smith A (1982) Symbol digit modalities test: manual. Western Psychological Services, Los Angeles

Woods SP, Childers PM, Ellis RJ, Guaman S, Grant I, Heaton RK, The HNRC Group (2006) A battery approach for measuring neuropsychological change. Arch Clin Neuropsychol 21(1):83–89. https://doi.org/10.1016/j.acn.2005.07.008CrossRefPubMed

Maubeuge N, Deloire MSA, Brochet B, Erhlé N, Charré-Morin J, Saubusse A (2021) RUet A, BICAFMS study investigators. Rev Neurol (Paris) 177(1–2):73–79. https://doi.org/10.1016/j.neurol.2020.04.028CrossRefPubMed

10.

Dusankova JB, Kalincik T, Havrdova E, Benedict RH (2012) Cross cultural validation of the minimal assessment of cognitive function in multiple sclerosis (MACFIMS) and the brief international cognitive assessment for multiple sclerosis (BICAMS). Clin Neuropsychol 2012(26):1186–1200. https://doi.org/10.1080/13854046.2012.725101CrossRef

11.

Beck AT, Epstein N, Brown G, Steer RA (1988) An inventory for measuring clinical anxiety: psychometric properties. J Consult Clin Psychol 56(6):893–897. https://doi.org/10.1037//0022-006x.56.6.893CrossRefPubMed

12.

Beck AT, Beamesderfer A (1974) Assessment of depression: the depression inventory. Mod Probl Pharmacopsychiatry 7:151–169CrossRefPubMed

13.

Collet L, Cottraux J (1986) The shortened Beck depression inventory (13 items). Study of the concurrent validity with the Hamilton scale and Widlocher’s retardation scale. Encephale 12:77–79PubMed

14.

Hobart J, Cano S (2009) Improving the evaluation of therapeutic interventions in multiple sclerosis: the role of new psychometric methods. Health Technol Assess 13:1–216. https://doi.org/10.3310/hta13120CrossRef

15.

Debouverie M, Pittion-Vouyovitch S, Louis S, Guillemin F (2007) Validity of a French version of the fatigue impact scale in multiple sclerosis. Mult Scler 13:1026–1032. https://doi.org/10.1177/1352458507077942CrossRefPubMed

16.

van der Hiele K, Spliethoff-Kamminga NGA, Ruimschotel RP, Middelkoop HAM, Visser LH (2012) The relationship between self-reported executive performance and psychological characteristics in multiple sclerosis. Eur J Neurol 19:562–569. https://doi.org/10.1111/j.1468-1331.2011.03538.xCrossRefPubMed

17.

Vernay D, Gerbaud L, Biolay S, Coste J, Debourse J, Aufauvre D, Beneton C, Colamarino R, Glanddier PY, Dordain G, Clavelou P (2000) Quality of life and multiple sclerosis: validation of the french version of the self-questionnaire (SEP-59). Rev Neurol (Paris) 156:247–263PubMed

18.

Vickrey BG, Hays RD, Harooni R, Myers LW, Ellison GW (1995) A health-related quality of life measure for multiple sclerosis. Qual Life Res 4:187–206. https://doi.org/10.1007/BF02260859CrossRefPubMed

19.

Honan CA, Brown RF, Hine DW (2014) The multiple sclerosis work difficulties questionnaire (MSWDQ): development of a shortened scale. Disabil Rehabil 36(8):635–641. https://doi.org/10.3109/09638288.2013.805258CrossRefPubMed

20.

Durand MJ, Vachon B, Hong QN, Imbeau D, Amick BC 3rd, Loisel P (2004) The cross-cultural adaptation of the work role functioning questionnaire in Canadian French. Int J Rehabil Res 27(4):261–268. https://doi.org/10.1097/00004356-200412000-00002CrossRefPubMed

21.

Poullet JB, Sima DM, Simonetti AW, De Neuter B, Vanhamme L, Lemmerling P, Van Huffel S (2007) An automated quantitation of short echo time MRS spectra in an open source software environment: AQSES. NMR Biomed 20(5):493–504. https://doi.org/10.1002/nbm.111227CrossRefPubMed

22.

Eriksson J, Kobelt G, Gannedahl M, Berg J (2019) Association between disability, cognition, fatigue, EQ-5D-3L domains, and utilities estimated with different Western European value sets in patients with multiple sclerosis. Value Heal 22(2):231–238. https://doi.org/10.1016/j.jval.2018.08.002CrossRef

23.

Visser L, Louapre C, Uyl-de Groot C, Redekop WK (2021) Health-related quality of life of multiple sclerosis patients: a European muti-country study. Arch Public Health 79(1):39. https://doi.org/10.1186/s13690-021-00561-zCrossRefPubMedPubMedCentral

24.

Pittion-Vouyovitch S, Debouverie M, Guillemin F, Vandenberghe N, Anxionnat R, Vespignani H (2006) Fatigue in multiple sclerosis is related to disability, depression and quality of life. J Neurol Sci 243(1–2):39–45. https://doi.org/10.1016/j.jns.2005.11.025CrossRefPubMed

25.

Gold SM, Schulz H, Mönch A, Schulz KH, Heesen C (2003) Cognitive impairment in multiple sclerosis does not affect reliability and validity of self-report health measures. Mult Scler J 9:404–410. https://doi.org/10.1191/1352458503ms927oaCrossRef

26.

Marrie RA, Chelune GJ, Miller DM, Cohen JA (2005) Subjective cognitive complaints relate to mild impairment of cognition in multiple sclerosis. Mult Scler 11(1):69-75. 33. https://doi.org/10.1191/1352458505ms1110oaCrossRefPubMed

27.

Miller DM, Bethoux F, Victorson D et al (2015) Validating Neuro-QoL short forms and targeted scales with people who have multiple sclerosis. Mult Scler J 22(6):830–841CrossRef

28.

Campbell J, Rashid W, Cercignani M, Langdon D (2017) Cognitive impairment among patients with multiple sclerosis: associations with employment and quality of life. Postgrad Med J 93:143–147. https://doi.org/10.1136/postgradmedj-2016-134071CrossRefPubMed

29.

Goverover Y, Chiaravalloti N, DeLuca J (2005) The relationship between self-awareness of neurobehavioral symptoms, cognitive functioning, and emotional symptoms in multiple sclerosis. Mult Scler 11:203–212. https://doi.org/10.1191/1352458505ms1153oaCrossRefPubMed

30.

Baumstarck K, Boyer L, Boucekine M, Michel P, Pelletier J, Auquier P (2013) Measuring the quality of life in patients with multiple sclerosis in clinical practice: a necessary challenge. Mult Scler Int 2013:524894. https://doi.org/10.1155/2013/524894CrossRefPubMedPubMedCentral

31.

Ribbons K, Lea R, Schofield PW, Lechner-Scott J (2017) Anxiety levels are independently associated with cognitive performance in an Australian multiple sclerosis patient cohort. J Neuropsychiatry Clin Neurosci 29:128–134. https://doi.org/10.1176/appi.neuropsych.16050085CrossRefPubMed

32.

Whitehouse CE, Fisk JD, Bernstein CN, Berrigan LI, Bolton JM, Graff LA, Hitchon CA et al (2019) Comorbid anxiety, depression, and cognition in MS and other immune mediated-disorders. Neurology 92(5):e406–e417. https://doi.org/10.1212/WNL.0000000000006854CrossRefPubMedPubMedCentral

33.

Goretti B, Viterbo RG, Portaccio E et al (2014) Anxiety state affects information processing speed in patients with multiple sclerosis. Neurol Sci 35(4):559-563. 10. https://doi.org/10.1007/s10072-013-1544-0CrossRefPubMed

34.

Morrow SA, Rosehart H, Pantazopoulos K (2015) Anxiety and depressive symptoms are associated with worse performance on objective cognitive tests in MS. J Neuropsychiatry Clin Neurosci 28:118–123. https://doi.org/10.1176/appi.neuropsych.15070167CrossRefPubMed

35.

Moller A, Wiedemann G, Rohde U, Backmund H, Sonntag A (1994) Correlates of cognitive impairment and depressive mood disorder in multiple sclerosis. Acta Psychiatr Scand 89(117–121):9. https://doi.org/10.1111/j.1600-0447.1994.tb01497.xCrossRef

36.

Good K, Clark CM, Oger J, Paty D, Klonoff H (1992) Cognitive impairment and depression in mild multiple sclerosis. J Nerv Ment Dis 180:730–732. https://doi.org/10.1097/00005053-199211000-00009CrossRefPubMed

37.

Snyder HR (2013) Major depressive disorder is associated with broad impairments on neuropsychological measures of executive function: a meta-analysis and review. Psychol Bull 139(81–132):46. https://doi.org/10.1037/a0028727CrossRef

38.

Eysenck MW, Derakshan N, Santos R, Calvo MG (2007) Anxiety and cognitive performance: attentional control theory. Emotion 7:336–353. https://doi.org/10.1037/1528-3542.7.2.336CrossRefPubMed

39.

Arnett PA, Higginson CI, Voss WD et al (1999) Depressed mood in multiple sclerosis: relationship to capacity demanding memory and attentional functioning. Neuropsychology 13(3):434-446. 5. https://doi.org/10.1037//0894-4105.13.3.434CrossRefPubMed

40.

Kinsinger SW, Lattie E, Mohr DC (2010) Relationship between depression, fatigue, subjective cognitive impairment, and objective neuropsychological functioning in patients with multiple sclerosis. Neuropsychology 24(5):573–580. https://doi.org/10.1037/a0019222CrossRefPubMedPubMedCentral

41.

Visser LH, van der Hiele K (2014) Self-reports of executive functioning in multiple sclerosis: to trust or not to trust. Neurodegener Dis Manag. https://doi.org/10.2217/nmt.14.15CrossRefPubMed

42.

Lysandropoulos AP, Absil J, Metens T, Mavroudakis N, Guisset F, Van Vlieberghe E, Smeets D, David P, Maertens A, Van Hecke W (2016) Quantifying brain volumes for multiple sclerosis patients follow-up win clinical practice—comparison of 1.5 and 3 tesla magnetic resonance imaging. Brain Behav 6:e00422. https://doi.org/10.1002/brb3.422CrossRefPubMedPubMedCentral

Titel: Patient-reported outcome measurements in a selective cohort of relapsing–remitting multiple sclerosis patients: relationships with physical disability, cognitive impairment, and MRI-derived metrics
verfasst von: Frédéric London
Souraya El Sankari
Alice De Haan
Zohra Benyahia
Gaëtane Landenne
Thierry Duprez
Vincent van Pesch
Publikationsdatum: 06.03.2023
Verlag: Springer International Publishing
Erschienen in: Acta Neurologica Belgica / Ausgabe 3/2023
Print ISSN: 0300-9009
Elektronische ISSN: 2240-2993
DOI: https://doi.org/10.1007/s13760-023-02225-x

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Schützt Olivenöl vor dem Tod durch Demenz?

10.05.2024 Morbus Alzheimer Nachrichten

Konsumieren Menschen täglich 7 Gramm Olivenöl, ist ihr Risiko, an einer Demenz zu sterben, um mehr als ein Viertel reduziert – und dies weitgehend unabhängig von ihrer sonstigen Ernährung. Dafür sprechen Auswertungen zweier großer US-Studien.

Bluttest erkennt Parkinson schon zehn Jahre vor der Diagnose

10.05.2024 Parkinson-Krankheit Nachrichten

Ein Bluttest kann abnorm aggregiertes Alpha-Synuclein bei einigen Menschen schon zehn Jahre vor Beginn der motorischen Parkinsonsymptome nachweisen. Mit einem solchen Test lassen sich möglicherweise Prodromalstadien erfassen und die Betroffenen früher behandeln.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Wartezeit nicht kürzer, aber Arbeit flexibler

Psychotherapie Medizin aktuell

Fünf Jahren nach der Neugestaltung der Psychotherapie-Richtlinie wurden jetzt die Effekte der vorgenommenen Änderungen ausgewertet. Das Hauptziel der Novellierung war eine kürzere Wartezeit auf Therapieplätze. Dieses Ziel wurde nicht erreicht, es gab jedoch positive Auswirkungen auf andere Bereiche.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Background

Objective

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2023

Reliability and validity of the Turkish version of general sleep disturbance scale (GSDS-T) in stroke

Dual task effect on upper and lower extremity skills in different stages of Parkinson’s disease

Post-traumatic syringomyelia resolution following surgical treatment: the moniliform syrinx with a better prognosis

Double-troubled brothers with GNE myopathy and cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy: a case report

A short and simple bedside test to detect cognitive fluctuations in patients with dementia with Lewy bodies